The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Precision medicine for neuroendocrine carcinomas: NABNEC study insights
Lorraine A. Chantrill, PhD, Wollongong Hospital, New South Wales, Australia, discusses the challenges in managing neuroendocrine carcinomas (NECs) due to their rarity and limited biological data. She emphasizes the need for precision medicine and personalized treatment strategies, acknowledging the current lag in understanding compared to more common tumor types. The Phase II NABNEC study (ACTRN12616000958482) aims to address this gap by collecting tumor samples and conducting translational research to identify potential biomarkers. The integration of these findings into clinical practice could enhance the management of high-grade neuroendocrine neoplasms, offering more tailored and effective treatment approaches. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
